DE69806067D1 - Bisulfatsalz eines hiv-protease-inhibitors - Google Patents

Bisulfatsalz eines hiv-protease-inhibitors

Info

Publication number
DE69806067D1
DE69806067D1 DE69806067T DE69806067T DE69806067D1 DE 69806067 D1 DE69806067 D1 DE 69806067D1 DE 69806067 T DE69806067 T DE 69806067T DE 69806067 T DE69806067 T DE 69806067T DE 69806067 D1 DE69806067 D1 DE 69806067D1
Authority
DE
Germany
Prior art keywords
protease inhibitor
hiv protease
bisulfate salt
bisulfate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69806067T
Other languages
English (en)
Other versions
DE69806067T2 (de
Inventor
Janak Singh
Madhusudhan Pudipeddi
D Lindrud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69806067(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE69806067D1 publication Critical patent/DE69806067D1/de
Application granted granted Critical
Publication of DE69806067T2 publication Critical patent/DE69806067T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69806067T 1998-01-20 1998-12-22 Bisulfatsalz eines hiv-protease-inhibitors Expired - Lifetime DE69806067T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20
PCT/US1998/027382 WO1999036404A1 (en) 1998-01-20 1998-12-22 Bisulfate salt of hiv protease inhibitor

Publications (2)

Publication Number Publication Date
DE69806067D1 true DE69806067D1 (de) 2002-07-18
DE69806067T2 DE69806067T2 (de) 2003-01-23

Family

ID=22104737

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69806067T Expired - Lifetime DE69806067T2 (de) 1998-01-20 1998-12-22 Bisulfatsalz eines hiv-protease-inhibitors

Country Status (39)

Country Link
US (1) US6087383A (de)
EP (1) EP1056722B1 (de)
JP (2) JP4860037B2 (de)
KR (1) KR100559283B1 (de)
CN (1) CN1116282C (de)
AR (1) AR014417A1 (de)
AT (1) ATE219057T1 (de)
AU (1) AU735875B2 (de)
BG (1) BG64774B1 (de)
BR (1) BR9814736A (de)
CA (1) CA2317736C (de)
CO (1) CO4970820A1 (de)
CZ (1) CZ293507B6 (de)
DE (1) DE69806067T2 (de)
DK (1) DK1056722T3 (de)
EE (1) EE04434B1 (de)
EG (1) EG23936A (de)
ES (1) ES2178300T3 (de)
GE (1) GEP20033026B (de)
HK (2) HK1033667A1 (de)
HU (1) HU227196B1 (de)
IL (2) IL137384A0 (de)
LT (1) LT4780B (de)
LV (1) LV12522B (de)
MY (1) MY114838A (de)
NO (1) NO315605B1 (de)
NZ (1) NZ504417A (de)
PE (1) PE20000185A1 (de)
PL (1) PL190744B1 (de)
PT (1) PT1056722E (de)
RO (1) RO118869B1 (de)
RU (1) RU2186070C2 (de)
SK (1) SK283975B6 (de)
TR (1) TR200001876T2 (de)
TW (1) TW531531B (de)
UA (1) UA59432C2 (de)
UY (1) UY25345A1 (de)
WO (1) WO1999036404A1 (de)
ZA (1) ZA9956B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448084A1 (en) 2001-05-22 2002-11-28 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US20040224917A1 (en) * 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI415635B (zh) 2004-05-28 2013-11-21 必治妥施貴寶公司 加衣錠片調製物及製備彼之方法
US7642049B2 (en) * 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
CA2657936C (en) * 2006-07-21 2017-01-10 Gilead Sciences, Inc. Antiviral protease inhibitors
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
JP2010529196A (ja) 2007-06-12 2010-08-26 コンサート ファーマシューティカルズ インコーポレイテッド アザペプチド誘導体
ES2449074T3 (es) * 2007-06-22 2014-03-18 Bristol-Myers Squibb Holdings Ireland Composiciones en forma de comprimidos que contienen atazanavir
KR20100033378A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
MX2009013499A (es) * 2007-06-22 2010-01-18 Bristol Myers Squibb Co Composiciones comprimidas que contienen atazanavir.
ATE503467T1 (de) * 2007-06-22 2011-04-15 Bristol Myers Squibb Co Tablettierte atazanavirhaltige zusammensetzungen
CN103480000A (zh) * 2007-06-29 2014-01-01 吉里德科学公司 治疗用组合物和方法
WO2009006203A1 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
US20110178305A1 (en) * 2008-05-08 2011-07-21 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
WO2010070611A1 (en) 2008-12-18 2010-06-24 Ranbaxy Laboratories Limited Atazanavir formulations
EP2376452A4 (de) 2009-01-12 2012-08-29 Hetero Research Foundation Neues polymorph aus atazanavir-sulfat
US8497383B2 (en) 2009-05-27 2013-07-30 Merck Sharp & Dohme Corp. HIV protease inhibitors
EP2272830A1 (de) 2009-06-18 2011-01-12 Esteve Química, S.A. Herstellungsverfahren für ein antivirales heterozyklisches Azahexan-Derivat
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
CA2777937C (en) 2009-10-26 2017-08-29 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
ES2688925T3 (es) 2010-01-27 2018-11-07 Viiv Healthcare Company Tratamiento antiviral
US20130005780A1 (en) 2010-03-01 2013-01-03 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
JP6158702B2 (ja) 2010-04-09 2017-07-05 ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｈｏｌｄｉｎｇｓ Ｉｒｅｌａｎｄ ｐＨの影響を改善したアタザナビル硫酸塩製剤
CA2849546A1 (en) 2010-09-28 2012-04-05 Ratiopharm Gmbh Dry processing of atazanavir
US20140343290A1 (en) 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
WO2014030173A2 (en) * 2012-08-24 2014-02-27 Laurus Labs Private Limited An improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
EP2956439B1 (de) 2013-02-12 2019-01-09 Cipla Limited Verfahren zur herstellung von atazanavirsulfat
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
LV12522B (en) 2000-10-20
JP2009102357A (ja) 2009-05-14
EG23936A (en) 2008-01-14
KR20010034221A (ko) 2001-04-25
JP2002509136A (ja) 2002-03-26
RO118869B1 (ro) 2003-12-30
US6087383A (en) 2000-07-11
TR200001876T2 (tr) 2000-11-21
GEP20033026B (en) 2003-07-25
DK1056722T3 (da) 2002-09-30
HU227196B1 (en) 2010-10-28
CZ20002564A3 (cs) 2000-10-11
UA59432C2 (uk) 2003-09-15
NO315605B1 (no) 2003-09-29
RU2186070C2 (ru) 2002-07-27
EE200000798A (et) 2002-06-17
AU2010199A (en) 1999-08-02
IL137384A0 (en) 2001-07-24
CA2317736C (en) 2004-11-02
CN1283188A (zh) 2001-02-07
ATE219057T1 (de) 2002-06-15
LT4780B (lt) 2001-04-25
EE04434B1 (et) 2005-02-15
NO20003692L (no) 2000-07-19
SK283975B6 (sk) 2004-06-08
KR100559283B1 (ko) 2006-03-15
TW531531B (en) 2003-05-11
LV12522A (en) 2000-08-20
CZ293507B6 (cs) 2004-05-12
EP1056722A4 (de) 2001-01-10
NZ504417A (en) 2001-09-28
HK1033458A1 (en) 2001-08-31
HUP0101389A3 (en) 2003-07-28
BR9814736A (pt) 2000-10-24
LT2000067A (en) 2000-11-27
BG64774B1 (bg) 2006-03-31
ZA9956B (en) 2000-07-05
PE20000185A1 (es) 2000-05-14
PT1056722E (pt) 2002-09-30
ES2178300T3 (es) 2002-12-16
EP1056722B1 (de) 2002-06-12
CN1116282C (zh) 2003-07-30
PL190744B1 (pl) 2006-01-31
MY114838A (en) 2003-01-31
CA2317736A1 (en) 1999-07-22
AR014417A1 (es) 2001-02-28
WO1999036404A1 (en) 1999-07-22
HUP0101389A2 (hu) 2001-08-28
CO4970820A1 (es) 2000-11-07
HK1033667A1 (en) 2001-09-14
EP1056722A1 (de) 2000-12-06
PL342019A1 (en) 2001-05-07
AU735875B2 (en) 2001-07-19
UY25345A1 (es) 2000-12-29
IL137384A (en) 2006-08-01
BG104618A (en) 2001-02-28
JP4860037B2 (ja) 2012-01-25
SK10622000A3 (sk) 2001-02-12
DE69806067T2 (de) 2003-01-23
NO20003692D0 (no) 2000-07-19

Similar Documents

Publication Publication Date Title
DE69806067D1 (de) Bisulfatsalz eines hiv-protease-inhibitors
PT1086076E (pt) Inibidores de sulfonamida de aspartil protease
NO20012980L (no) Proteaseinhibitorer
ATE264339T1 (de) Serine protease inhibitoren
NO995433D0 (no) Protease-inhibitorer
NO20011966L (no) Serin-protease-inhibitor
NO20004696L (no) Kinoloner som serinproteaseinhibitorer
ATE223909T1 (de) Sulfamide-metalloprotease inhibitoren
DK1686113T3 (da) Inhibitorer af aspartylprotease
NO995434D0 (no) Proteaseinhibitorer
NO995435D0 (no) Protease-inhibitorer
DE59806475D1 (de) Urokinase-inhibitoren
NO995268D0 (no) Proteaseinhibitorer
NO20011388D0 (no) Hydroksamat-inneholdende cystein- og serinproteasehemmere
DK1066276T3 (da) Fremgangsmåde til syntese af HIV protease inhibitor
DK1077945T3 (da) Isoquinoliner som urokinaseinhibitorer
NO995822D0 (no) Sulfatsalt av en HIV-proteaseinhibitor som har forbedret oral absorpsjon og biotilgjengelighet
NO994415D0 (no) HIV proteaseinhibitorer
SE0004239D0 (sv) New use of an inhibitor
MA26429A1 (fr) Inhibiteurs de protease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition